Companies: 10,795·Total market cap: $144.5T
Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPAOTCHealthcare● Active
$0.06
$-0.02(-23.75%)
Market Cap$710266
P/E Ratio—
52W High$0.25
52W Low$0.033
ForecastMarket CapPE Ratio

Hepion Pharmaceuticals, Inc.（HEPA）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

hepa · 股价预测 · 3 位分析师（近3月）· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 3 位华尔街分析师

SellBuy

Hold

3 位分析师

共识

评级分布

Strong Buy
0
Buy
1
Hold
2
Sell
0
Strong Sell
0
合计: 3 · 买入占比: 33.3%

12 个月目标价

High

$70.00

Consensus

$70.00

+114654.1% upside

Low

$70.00

Median: $70 · Last Close: $0.06

Hepion Pharmaceuticals, Inc.（HEPA）的分析师共识为 Hold，基于过去 3 个月内 3 位华尔街分析师的评级。HEPA 的 12 个月平均目标价为 $70.00，相对当前价 $0.06 代表 +114654.1% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

📅
财报窗口期

在 ±3 天财报窗口期内暂停短期预测，以避免不可靠信号。

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Elevated Volatility — Earnings Window Active (±3 days)· Technical signals still shown. M3 predictions paused.

Market Sentiment

NEUTRAL

Based on 14 technical indicators

0%57%43%
0Buy
8Neutral
6Sell
RSI (14)38.3Neutral
MACDNEUTRAL

Refreshes daily from EOD close

Moving Averages · HEPA · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$0.07SELL
MA 10$0.07SELL
MA 20$0.08SELL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $HEPA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.07SELL
EMA 10$0.07SELL
EMA 20$0.07SELL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $HEPA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Brookline Capital2023-12-07
Downgrade ↓
Buy→Hold
Cantor Fitzgerald2022-02-28
Maintains
Overweight→Overweight
Brookline Capital2019-11-22
Maintains
Buy→Buy
Maxim Group2019-03-20
Downgrade ↓
Buy→Hold
Maxim Group2018-07-10
Upgrade ↑
Hold→Buy
Maxim Group2016-05-06
Maintains
Buy→Buy

Wall Street analysts have recently issued updated ratings on Hepion Pharmaceuticals, Inc. (HEPA) stock. Of the recent 6 rating actions, 1 were upgrades and 2 were downgrades. 3 analysts currently cover HEPA.

分析师推荐趋势

Buy ratings1 → 0↓ 1
Hold ratings0 → 1↑ +1
Sell ratings0 → 0

HEPA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$20M

Revenue Next Year

$0M

↓ 100.0% YoY

EPS This Year

$-72800.00

EPS Next Year

$-571.50

↓ 99.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast HEPA EPS of $-72800.00 for the current fiscal year, based on estimates from 1 analysts. The HEPA revenue forecast is $20M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

HEPA 股价预测由两类独立数据源支撑：来自 3 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。HEPA 的共识目标价为 $70.00（+114654.1% 上行空间），分析师共识为 Hold。

Hepion Pharmaceuticals, Inc. 在 OTC 上市，代码 HEPA。HEPA 在 2027 年的整体展望偏中性/分化，在覆盖分析师中约 33% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

HEPA 预测 · 8 个问题

根据 3 位华尔街分析师，HEPA 的 12 个月平均目标价为 $70.00，最高 $70.00、最低 $70.00。若有图表，中位目标价可在上方查看。相对当前价 $0.06，隐含约 +114654.1% 的上行空间。

HEPA 目标价HEPA 分析师目标价HEPA 12个月目标价目标价 HEPA

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.